Nanoscope Therapeutics Names Glenn Sblendorio as Chairman of the Board

Nanoscope Therapeutics announced the appointment of Glenn Sblendorio as Chairman of the Board, effective immediately. 

In a news release, Nanoscope said Mr. Sblendorio's comprehensive understanding of finance and business development will assist in guiding Nanoscope through its mission to bring hope for renewed sight to millions of people affected by retinal degenerative diseases for which no cures currently exist.

"I am honored to join Nanoscope as Chairman of the Board. The company's commitment to advancing novel treatments for retinal degenerative diseases aligns with my passion for making a meaningful impact in the retina space. I look forward to working collaboratively with the board and leadership team to drive innovation and contribute to the realization of our shared mission," Mr. Sblendorio said.

Mr. Sblendorio has more than 30 years of executive leadership experience in the ophthalmic industry, most recently holding leadership roles at Iveric bio (formerly Ophthotech)(, including CEO, President, and Director. Additionally, he served as President, CFO, and Director at The Medicines Company, and as EVP and CFO at Eyetech Pharmaceuticals. Earlier in his career, Mr. Sblendorio was a Managing Director at MPM Capital Advisors, LLC, and held various senior financial positions at Hoffman-La Roche.